Nabriva Therapeutics plc (NBRVF)

Nabriva Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Jan 30, 2026	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Market Capitalization	0	6	34	51	125	98
Market Cap Growth	-99.99%	-82.95%	-33.41%	-59.13%	27.62%	-55.43%
Enterprise Value	-	-3	-10	19	83	-2
Last Close Price	0.00	1.89	14.97	60.50	330.00	365.00
PS Ratio	0.00	0.16	1.18	10.15	13.16	10.13
PB Ratio	0.00	1.76	0.64	1.54	3.02	1.43
P/TBV Ratio	-	1.76	0.64	1.54	3.03	1.43
EV/Sales Ratio	-	-	-	3.77	8.71	-
Debt / Equity Ratio	-0.03	1.59	0.15	0.23	0.84	0.35
Asset Turnover	0.90	0.66	0.42	0.07	0.09	0.09
Inventory Turnover	-	3.90	2.54	4.88	-	-
Quick Ratio	0.25	0.69	2.71	2.44	5.35	6.04
Current Ratio	0.38	1.13	3.59	3.09	5.48	6.11
Return on Equity (ROE)	-602.21%	-201.91%	-114.36%	-186.76%	-150.61%	-152.33%
Return on Assets (ROA)	-92.85%	-61.56%	-43.53%	-54.18%	-48.58%	-49.91%
Return on Invested Capital (ROIC)	-	-1131.87%	-735.72%	-	-	-
Return on Capital Employed (ROCE)	311.20%	-1333.90%	-82.90%	-165.70%	-102.60%	-88.90%
Earnings Yield	-8522291.02%	-987.50%	-145.57%	-136.22%	-66.32%	-117.37%
FCF Yield	-2016099.07%	-637.59%	-175.40%	-140.06%	-57.66%	-74.60%
Buyback Yield / Dilution	-34.65%	-54.67%	-237.48%	-73.12%	-46.07%	-70.28%

Updated Oct 19, 2023. Source: S&P Global Market Intelligence. Standard template. Financial Sources.